Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas

Leukemia and Lymphoma

Volumn 44, Issue 9, 2003, Pages 1529-1533

  Ribrag, V ^a   Koscielny, S ^a   Vantelon, J M ^a   Ferme C ^a   Rideller, K ^a   Carde, P ^a   Bourhis, J H ^a   Munck, J N ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Irinotecan; Non Hodgkin lymphoma; Salvage therapy

Indexed keywords

ATROPINE; INFUSION FLUID; IRINOTECAN; LOPERAMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II; DIARRHEA; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; LIFE TABLES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEUTROPENIA; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037560302     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000099643     Document Type: Article

References (11)

1. Vose, J.M. (1998) "Current approaches to the management of non-Hodgkin's lymphoma", Semin. Oncol. 25, 483-491.
2. Philip, T., Guglielmi, C., Hegenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.-Y., Harrousseau, L-L., Coiffier, B., Biron, P., Mandelli, E and Ghauvin, F. (1995) "Autologous bone marrow tranplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma", N. Engl. J. Med. 333, 1540-1545.
3. Cabanillas, F., Velasquez, W.S., McLaughlin, P., Jagannath, S., Hagemeister, F., Redman, J.R., et al. (1988) "Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease", Semin. Hematol. 25, 47-50.
4. Armitage, J.O., Vose, J.M., Bierman, P.J. and Bishop, M.R. (1994) "Salvage therapy for patients with lymphoma", Semin. Oncol. 21, 82-85.
5. Abigerges, D., Armand, J.P., Chabot, G.G., Da Costa, L., Fadel, E., Cote, C., Hèrait, P. and Gandia, D. (1994) "Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea", J. Natl Cancer Inst. 86, 446-449.
6. Cheson, B.D., Horning, S.J., Coiffier, B., et al. (1999) "Report of an International workshop to standardize response criteria for non-Hodgkin's lymphomas", J. Clin. Oncol. 17, 1244.
7. Ohno, R., Okada, K., Masaoka, T., Kuramato, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaku, S. and Ota, K. (1990) "An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma", J. Clin. Oncol. 8, 1907-1912.
8. Sgiyama, K., Omachi, K., Fufiwara, K., Saotome, T., Mizunuma, N., Takahashi, S., Ito, Y., Aiba, K. and Horikoshi, N. (2002) "Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma", Cancer 94, 594-600.
9. Ohta, K., Ohno, R., Shirakawa, S., Masaoka, T., Okada, H., Ohashi, Y. and Tagushi, T. (1994) "Late phase II clinical study of irinotecan hydrochloryde (CPT-11) in the treatment of malignant lymphoma and leukemia", Jpn J. Cancer Chemother 21, 1047-1055.
10. Rothenberg, M.L., Kuhn, J.G., Burris, H.A., III, Nelson, J., Eckardt, J.R., Tristan-Morales, M., Hilsenbeck, S.G., Weiss, G.R., Smith, L.S. and Rodriguez (1993) "Phase I and pharmacokinetic trial of weekly CPT-11", J. Clin. Oncol. 11, 2194-21204.
11. Abigerges, D., Chabot, G.G., Armand, J.P., Herait, P., Gouyette, A. and Gandia, D. (1995) "Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients", J. Clin. Oncol. 13, 210-221.